LINDSEY KELLEY: Open Payments
NPI 1134747850 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$432 in 17 payments from 10 companies in 2025. Trend: 2023 $431 · 2024 $636 · 2025 $432
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $146 |
| ABBVIE INC. | 4 | $87 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 2 | $34 |
| Lilly USA, LLC | 1 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
Products named: Ozempic, QULIPTA, Auvelity, Veozah, ZEPBOUND, SKYRIZI, IBSRELA, TRELEGY ELLIPTA.
Industry payments across LA — which companies pay providers there.
